Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

被引:0
作者
Tove Godskesen
Peter Nygren
Karin Nordin
Mats Hansson
Ulrik Kihlbom
机构
[1] Uppsala University,Centre for Research Ethics & Bioethics
[2] Uppsala University,Department of Radiology, Oncology, and Radiation Sciences
[3] Uppsala University,Department of Public Health and Caring Sciences
[4] University of Bergen,Department of Global Public Health and Primary Care
来源
Supportive Care in Cancer | 2013年 / 21卷
关键词
Cancer; Clinical trials; Ethics; Sweden;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3137 / 3142
页数:5
相关论文
共 101 条
[1]  
Appelbaum PS(1982)The therapeutic misconception: informed consent in psychiatric research Int J Law Psychiatry 5 319-329
[2]  
Roth LH(2001)The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial Cancer 91 1949-1955
[3]  
Lidz C(2000)Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences Psychooncol 9 314-322
[4]  
Cohen L(2002)Informed consent and decision-making: patients’ experiences of the process of recruitment to phases I and II anti-cancer drug trials Patient Educ Couns 46 31-38
[5]  
de Moor C(1999)Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective J Clin Oncol 17 1601-1617
[6]  
Amato RJ(2000)Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients IRB 22 6-14
[7]  
Cox K(2011)A new, simple and objective prognostic score for phase I cancer patients Eur J Cancer 47 1152-1160
[8]  
Cox K(2005)Payment of clinical research subjects J Clin Invest 115 1681-1687
[9]  
Daugherty CK(2004)Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness Nurse Educ Today 24 105-112
[10]  
Daugherty CK(2003)Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents Brit J Cancer 89 1166-1171